

Denis Glotz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/123727/publications.pdf>

Version: 2024-02-01

124
papers

13,769
citations

34016

52
h-index

21474

114
g-index

136
all docs

136
docs citations

136
times ranked

9210
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody-Mediated Rejection Criteria - an Addition to the Banff 1997 Classification of Renal Allograft Rejection. American Journal of Transplantation, 2003, 3, 708-714.	2.6	960
2	The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. American Journal of Transplantation, 2018, 18, 293-307.	2.6	813
3	Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival. New England Journal of Medicine, 2013, 369, 1215-1226.	13.9	746
4	Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2010, 21, 1398-1406.	3.0	689
5	Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation. Transplantation, 2013, 95, 19-47.	0.5	679
6	The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. American Journal of Transplantation, 2017, 17, 28-41.	2.6	551
7	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell-mediated and antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 2318-2331.	2.6	437
8	Banff 2011 Meeting Report: New Concepts in Antibody-Mediated Rejection. American Journal of Transplantation, 2012, 12, 563-570.	2.6	379
9	Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet, The, 2013, 381, 313-319.	6.3	308
10	Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ, The, 2014, 349, g6679-g6679.	3.0	252
11	Desensitization and Subsequent Kidney Transplantation of Patients Using Intravenous Immunoglobulins (IVIg). American Journal of Transplantation, 2002, 2, 758-760.	2.6	248
12	IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. Journal of the American Society of Nephrology: JASN, 2016, 27, 293-304.	3.0	244
13	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. Journal of the American Society of Nephrology: JASN, 2015, 26, 1721-1731.	3.0	243
14	The evaluation of renal function and disease in patients with cirrhosis. Journal of Hepatology, 2010, 52, 605-613.	1.8	218
15	Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. Journal of the American Society of Nephrology: JASN, 2017, 28, 1912-1923.	3.0	208
16	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 2018, 18, 1604-1614.	2.6	205
17	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ: British Medical Journal, 2019, 366, 14923.	2.4	191
18	INDUCTION VERSUS NONINDUCTION IN RENAL TRANSPLANT RECIPIENTS WITH TACROLIMUS-BASED IMMUNOSUPPRESSION1. Transplantation, 2001, 72, 1050-1055.	0.5	168

#	ARTICLE	IF	CITATIONS
19	COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence and Clinical Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2413-2423.	3.0	161
20	SUPPRESSION OF HLA-SPECIFIC ALLOANTIBODIES BY HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS (IVIg). <i>Transplantation</i> , 1993, 56, 335-337.	0.5	158
21	A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1. <i>Transplantation</i> , 2003, 75, 844-851.	0.5	150
22	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. <i>BMJ, The</i> , 2015, 351, h3557.	3.0	146
23	Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy. <i>Kidney International</i> , 1998, 53, 918-925.	2.6	144
24	Renal Histopathological Lesions After Orthotopic Liver Transplantation (OLT). <i>American Journal of Transplantation</i> , 2005, 5, 1120-1129.	2.6	142
25	Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance. <i>JAMA Internal Medicine</i> , 2019, 179, 1365.	2.6	125
26	Post-Transplantation Lymphoproliferative Disorder After Kidney Transplantation: Report of a Nationwide French Registry and the Development of a New Prognostic Score. <i>Journal of Clinical Oncology</i> , 2013, 31, 1302-1309.	0.8	122
27	Early Epithelial Phenotypic Changes Predict Graft Fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1584-1591.	3.0	121
28	Molecular Microscope Strategy to Improve Risk Stratification in Early Antibody-Mediated Kidney Allograft Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2267-2277.	3.0	121
29	Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. <i>Kidney International</i> , 2019, 96, 189-201.	2.6	117
30	A Simple Clinico-Histopathological Composite Scoring System Is Highly Predictive of Graft Outcomes in Marginal Donors. <i>American Journal of Transplantation</i> , 2008, 8, 2325-2334.	2.6	116
31	Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 702-715.	3.0	111
32	C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study. <i>American Journal of Transplantation</i> , 2016, 16, 1596-1603.	2.6	110
33	Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2891-2896.	3.3	107
34	Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. <i>American Journal of Transplantation</i> , 2019, 19, 2876-2888.	2.6	95
35	Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 620-635.	3.0	94
36	Donor-Specific Antibodies Accelerate Arteriosclerosis after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 975-983.	3.0	88

#	ARTICLE	IF	CITATIONS
37	Acute respiratory failure in kidney transplant recipients: a multicenter study. <i>Critical Care</i> , 2011, 15, R91.	2.5	80
38	T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. <i>American Journal of Transplantation</i> , 2018, 18, 377-390.	2.6	76
39	Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002572.	3.9	76
40	Incidence of Delayed Graft Function and Wound Healing Complications After Deceased-Donor Kidney Transplantation Is not Affected by De Novo Everolimus. <i>Transplantation</i> , 2009, 88, 69-76.	0.5	75
41	Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. <i>American Journal of Medicine</i> , 2001, 111, 417-418.	0.6	72
42	Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. <i>Transplant International</i> , 2010, 23, 1084-1093.	0.8	68
43	Epitope Analysis of HLA-DQ Antigens. <i>Transplantation</i> , 2014, 98, 157-166.	0.5	68
44	Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. <i>American Journal of Transplantation</i> , 2019, 19, 2865-2875.	2.6	67
45	Outcome of relapse in lupus nephritis: Roles of reversal of renal fibrosis and response of inflammation to therapy. <i>Kidney International</i> , 2002, 61, 2176-2186.	2.6	65
46	<i>Candida albicans</i> Arteritis Transmitted by Conservative Liquid After Renal Transplantation: A Report of Four Cases and Review of the Literature. <i>Transplantation</i> , 2006, 82, 1163-1167.	0.5	63
47	Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. <i>Transplant International</i> , 2004, 17, 1-8.	0.8	61
48	Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection. <i>American Journal of Transplantation</i> , 2019, 19, 1972-1988.	2.6	60
49	Chronic Kidney Dysfunction in Patients Alive without Relapse 2 Years after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1251-1257.	2.0	56
50	Thymoglobulin Induction and Sirolimus Versus Tacrolimus in Kidney Transplant Recipients Receiving Mycophenolate Mofetil and Steroids. <i>Transplantation</i> , 2010, 89, 1511-1517.	0.5	56
51	Regulatory T Cells in Kidney Allograft Infiltrates Correlate With Initial Inflammation and Graft Function. <i>Transplantation</i> , 2010, 89, 194-199.	0.5	55
52	Oxidative Stress Mediates a Reduced Expression of the Activating Receptor NKG2D in NK Cells from End-Stage Renal Disease Patients. <i>Journal of Immunology</i> , 2009, 182, 1696-1705.	0.4	53
53	Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 606-619.	3.0	53
54	Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. <i>Molecular Immunology</i> , 1983, 20, 1401-1404.	1.0	52

#	ARTICLE	IF	CITATIONS
55	Antibodies eluted from acutely rejected renal allografts bind to and activate human endothelial cells. <i>Human Immunology</i> , 2000, 61, 518-527.	1.2	51
56	Endothelial Cells as Targets of Allograft Rejection. <i>Transplantation</i> , 2006, 82, S19-S21.	0.5	50
57	The role of <sc>T</sc>hymoglobin induction in kidney transplantation: an update. <i>Clinical Transplantation</i> , 2012, 26, E450-64.	0.8	49
58	Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 625-639.	3.0	48
59	Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2044-2046.	0.4	45
60	The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders. <i>Transplantation</i> , 2012, 94, 784-793.	0.5	45
61	Preliminary results of transplantation with kidneys donated after cardiocirculatory determination of death: a French single-centre experience. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2583-2587.	0.4	44
62	Biopsyâ€confirmed <i>de novo</i> renal cell carcinoma (RCC) in renal grafts: a singleâ€centre management experience in a 2396 recipient cohort. <i>BJU International</i> , 2012, 109, 195-199.	1.3	43
63	Circulating donor-specific anti-HLA antibodies areÂa major factor in premature and acceleratedÂallograft fibrosis. <i>Kidney International</i> , 2017, 92, 729-742.	2.6	43
64	Access to, and outcome of, renal transplantation according to treatment modality of end-stage renal disease in France. <i>Kidney International</i> , 2005, 67, 2448-2453.	2.6	41
65	New insights in antibody-mediated rejection. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 597-604.	1.0	41
66	Determinants and Outcomes of Accelerated Arteriosclerosis. <i>Circulation Research</i> , 2015, 117, 470-482.	2.0	41
67	Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients. <i>American Journal of Transplantation</i> , 2018, 18, 3065-3071.	2.6	41
68	Specificity and cross-reactive idiotypes of anti-glomerular basement membrane autoantibodies in HgCl ₂ -induced autoimmune glomerulonephritis. <i>European Journal of Immunology</i> , 1990, 20, 93-100.	1.6	40
69	Trajectories of glomerular filtration rate and progression to end stage kidney disease afterÂkidney transplantation. <i>Kidney International</i> , 2021, 99, 186-197.	2.6	40
70	Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 397-409.	3.0	40
71	Hemolytic Uremic Syndrome: Recurrence after Renal Transplantation. <i>Medicine (United States)</i> , 2000, 79, 90-102.	0.4	39
72	Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. <i>Kidney International</i> , 2018, 94, 773-787.	2.6	38

#	ARTICLE	IF	CITATIONS
73	HLA-DQ alloantibodies directly activate the endothelium and compromise differentiation of FoxP3high regulatory T lymphocytes. <i>Kidney International</i> , 2019, 96, 689-698.	2.6	38
74	Molecular characterization of the VH region of murine autoantibodies from neonatal and adult BALB/c mice. <i>European Journal of Immunology</i> , 1989, 19, 453-457.	1.6	37
75	The Role of the Endothelium during Antibody-Mediated Rejection: From Victim to Accomplice. <i>Frontiers in Immunology</i> , 2018, 9, 106.	2.2	37
76	Immunological function of the endothelial cell within the setting of organ transplantation. <i>Immunology Letters</i> , 2011, 139, 1-6.	1.1	36
77	Dual Invasive Infection with <i>Phaeoacremonium parasiticum</i> and <i>Paraconiothyrium cyclothyrioides</i> in a Renal Transplant Recipient: Case Report and Comprehensive Review of the Literature of <i>Phaeoacremonium</i> Phaeohyphomycosis. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2084-2094.	1.8	33
78	Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: Effects on long-term renal function after liver transplantation. <i>Journal of Hepatology</i> , 2012, 57, 572-576.	1.8	32
79	Chronic Interstitial Nephritis in An HIV Type-1-Infected Patient Receiving Ritonavir-Boosted Atazanavir. <i>Antiviral Therapy</i> , 2011, 16, 119-121.	0.6	31
80	Renal biopsy practice in France: results of a nationwide study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3579-3585.	0.4	30
81	Human Immunoglobulins Inhibit Thrombin-induced Ca ²⁺ Movements and Nitric Oxide Production in Endothelial Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 26473-26476.	1.6	27
82	Detection and quantitation of BK virus DNA by real-time polymerase chain reaction in the LT-ag gene in adult renal transplant recipients. <i>Journal of Virological Methods</i> , 2006, 131, 21-27.	1.0	26
83	Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. <i>Kidney International</i> , 2001, 60, 341-349.	2.6	25
84	Early Steroid Withdrawal and Optimization of Mycophenolic Acid Exposure in Kidney Transplant Recipients Receiving Mycophenolate Mofetil. <i>Transplantation</i> , 2011, 92, 1244-1251.	0.5	24
85	Successful endoluminal thrombo-aspiration of renal graft venous thrombosis. <i>Transplant International</i> , 2000, 13, 82-86.	0.8	23
86	Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes. <i>Human Immunology</i> , 2004, 65, 1307-1318.	1.2	23
87	Donor Specific Antibodies are not only directed against HLA-DR: Minding your Ps and Qs. <i>Human Immunology</i> , 2016, 77, 1092-1100.	1.2	23
88	Regulation of the CD4+ T cell allo-immune response by endothelial cells. <i>Human Immunology</i> , 2012, 73, 1269-1274.	1.2	20
89	The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation. <i>Nature Medicine</i> , 2022, 28, 989-998.	15.2	20
90	Antidonor Antibodies and Transplantation: How to Deal with Them Before and After Transplantation. <i>Transplantation</i> , 2005, 79, S30-S32.	0.5	19

#	ARTICLE	IF	CITATIONS
91	Can solid phase assays be better utilized to measure efficacy of antibody removal therapies?. Human Immunology, 2016, 77, 624-630.	1.2	19
92	Prospective, multicenter, controlled study of quality of life, psychological adjustment process and medical outcomes of patients receiving a preemptive kidney transplant compared to a similar population of recipients after a dialysis period of less than three years – The PreKit-QoL study protocol. BMC Nephrology, 2016, 17, 11.	0.8	18
93	Surrogate Endpoints for Late Kidney Transplantation Failure. Transplant International, 0, 35, .	0.8	18
94	PROLONGED ALLOGRAFT SURVIVAL THROUGH CONDITIONAL AND SPECIFIC ABLATION OF ALLOREACTIVE T CELLS EXPRESSING A SUICIDE GENE1. Transplantation, 2000, 69, 2154-2161.	0.5	17
95	A Case Report of Adenovirus-Related Acute Interstitial Nephritis in a Patient With AIDS. American Journal of Kidney Diseases, 2008, 51, 121-126.	2.1	16
96	Pulsatile Perfusion Preservation for Expanded-Criteria Donors Kidneys: Impact on Delayed Graft Function Rate. International Journal of Artificial Organs, 2011, 34, 513-518.	0.7	16
97	Natural Killer Lymphocytes Are Dysfunctional in Kidney Transplant Recipients on Diagnosis of Cancer. Transplantation, 2015, 99, 2422-2430.	0.5	16
98	Endothelial Cell Amplification of Regulatory T Cells Is Differentially Modified by Immunosuppressors and Intravenous Immunoglobulin. Frontiers in Immunology, 2017, 8, 1761.	2.2	16
99	Kidney Allograft Fibrosis After Transplantation From Uncontrolled Circulatory Death Donors. Transplantation, 2015, 99, 409-415.	0.5	15
100	Inflammation Determines the Capacity of Allogenic Endothelial Cells to Regulate Human Treg Expansion. Frontiers in Immunology, 2021, 12, 666531.	2.2	14
101	Therapeutic failure of cinacalcet in a renal transplant patient presenting hyperparathyroidism with severe hypercalcaemia. Nephrology Dialysis Transplantation, 2005, 20, 2865-2865.	0.4	13
102	Acute vascular humoral rejection in a sensitized cardiac graft recipient: diagnostic value of C4d immunofluorescence. Human Pathology, 2004, 35, 385-388.	1.1	12
103	What is the relevance of systematic aorto-femoral Doppler ultrasound in the preoperative assessment of patients awaiting first kidney transplantation: a monocentric prospective study. Nephrology Dialysis Transplantation, 2010, 25, 270-274.	0.4	12
104	T-Cell Suicide Gene Therapy for Organ Transplantation: Induction of Long-Lasting Tolerance to Allogeneic Heart without Generalized Immunosuppression. Molecular Therapy, 2000, 2, 596-601.	3.7	11
105	Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?. Nephrology Dialysis Transplantation, 2006, 21, 2696-2702.	0.4	11
106	Calcineurin Inhibitor-Free Monotherapy in Human Leukocyte Antigen-Identical Live Donor Renal Transplantation. Transplantation, 2011, 91, 330-333.	0.5	11
107	Evidence for an important role of both complement-binding and noncomplement-binding donor-specific antibodies in renal transplantation. Current Opinion in Organ Transplantation, 2016, 21, 433-440.	0.8	11
108	Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation. Transplant International, 0, 35, .	0.8	10

#	ARTICLE	IF	CITATIONS
109	Prediction of chronic kidney disease after acute kidney injury in ICU patients: study protocol for the PREDICT multicenter prospective observational study. <i>Annals of Intensive Care</i> , 2018, 8, 77.	2.2	8
110	Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e18-e19.	0.7	7
111	Study of the Allogeneic Response Induced by Endothelial Cells Expressing HLA Class II After Lentiviral Transduction. <i>Methods in Molecular Biology</i> , 2013, 960, 461-472.	0.4	7
112	A paraneoplastic membranoproliferative glomerulonephritis with isolated C3 deposits associated with hairy cell leukaemia. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2026-2028.	0.4	6
113	Minimising the clinical impact of the alloimmune response through effective histocompatibility testing for organ transplantation. <i>Transplant Immunology</i> , 2012, 27, 83-88.	0.6	6
114	Kidney graft dysfunction in simultaneous pancreas-kidney recipients after pancreas failure: analysis of early and late protocol biopsies. <i>Clinical Transplantation</i> , 2013, 27, E249-55.	0.8	6
115	Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation. <i>Transplant International</i> , 0, 35, .	0.8	6
116	Recurrent Acute Glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 1991, 17, 228-230.	2.1	5
117	Characteristics of T- and NK-cell Lymphomas After Renal Transplantation: A French National Multicentric Cohort Study. <i>Transplantation</i> , 2021, 105, 1858-1868.	0.5	3
118	Idiotype regulation of self responses, autoantibody V regions and neonatal B cell repertoire. <i>Immunology Letters</i> , 1987, 16, 277-282.	1.1	2
119	Diagnostic criteria for kidney transplant rejection: a call to action – Authors' reply. <i>Lancet, The</i> , 2013, 381, 1458-1459.	6.3	2
120	Modulation of the formation of the human C3 amplification convertase of complement by polyelectrolytes. <i>Agents and Actions</i> , 1981, 11, 645-646.	0.7	1
121	Autoantibody Idiotype and Neonatal B Cell Repertoire. <i>Viral Immunology</i> , 1989, 2, 263-269.	0.6	0
122	The blurring frontier between autoimmunity and alloimmunity. <i>Current Opinion in Organ Transplantation</i> , 2016, 21, 349.	0.8	0
123	An activated endothelium after organ transplantation: the pathogenesis of rejection. , 2021, , 69-76.		0
124	Transplantation R�onale Abo Incompatible. <i>Journal Medical Libanais</i> , 2015, 63, 159-163.	0.0	0